Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01451658|
Recruitment Status : Unknown
Verified October 2011 by Taipei Veterans General Hospital, Taiwan.
Recruitment status was: Recruiting
First Posted : October 14, 2011
Last Update Posted : October 14, 2011
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Varices Hemorrhage Hepatocellular Carcinoma||Drug: propranolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||October 2012|
No Intervention: EVL or GVS treatment
Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)
No Intervention: Endoscopic treatment alone versus combined propranolol
Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Other Name: propranolol:Inderal,Cardolol
- Rebleeding [ Time Frame: 2 year ]
- complication survival [ Time Frame: 2 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01451658
|Veteran General Hospital-Taipei||Recruiting|
|Taipei, Ming-Chih Hou, MD, Taiwan, 11217|
|Contact: Ming Chih Hou, MD 886-2-28712121 ext 3763 firstname.lastname@example.org|
|Principal Investigator: Ming Chih Hou, MD|